Alamar Biosciences, Inc. (ALMR) vs Arcutis Biotherapeutics, Inc. (ARQT)
A side-by-side comparison of Alamar Biosciences, Inc. and Arcutis Biotherapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALMR
Alamar Biosciences, Inc.
$35.01HealthcareDelayed quote: Oct 6, 2026, 10:30 AM EDT
ARQT
Arcutis Biotherapeutics, Inc.
$24.24HealthcareDelayed quote: Oct 6, 2026, 10:30 AM EDT
Total return — ALMR vs ARQT
growth of $100 · dividends reinvested · last 1yALMR +73.3% (+73.3%/yr)ARQT +2.5% (+2.5%/yr)ALMR compounded faster over this window
ALMR ARQT
ALMR vs ARQT: by the numbers
- •ARQT is the larger company ($3.03B vs $2.43B market cap).
- •ARQT is profitable (6.15% net margin) while ALMR runs a net loss (-40.18%).
Metrics side by side
Valuation
| Metric | ALMR | ARQT |
|---|---|---|
| P/E ratio | N/A | 116.24 |
| Forward P/E | N/A | 48.75 |
| P/S ratio | N/A | 6.53 |
| P/B ratio | 7.76 | 13.74 |
| EV / EBITDA | N/A | 83.63 |
| FCF yield | N/A | 1.29% |
Profitability
| Metric | ALMR | ARQT |
|---|---|---|
| Gross margin | 56.20% | 91.14% |
| Operating margin | -42.22% | -3.25% |
| Net margin | -40.18% | 6.15% |
| ROE | N/A | 12.93% |
| ROIC | -26.95% | 9.95% |
Growth (annualized)
| Metric | ALMR | ARQT |
|---|---|---|
| Total return CAGR (5Y) | N/A | -0.28% |
Frequently asked
- Is ALMR or ARQT more profitable?
- ARQT runs the higher net margin — ALMR at -40.18% versus ARQT at 6.15%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.